Advertisement

Intrathecal and Oral Baclofen Use in Adults With Spinal Cord Injury: A Systematic Review of Efficacy in Spasticity Reduction, Functional Changes, Dosing, and Adverse Events

      Abstract

      Objective

      To examine the efficacy, dosing, and safety profiles of intrathecal and oral baclofen in treating spasticity after spinal cord injury (SCI).

      Data Sources

      PubMed and Cochrane Databases were searched from 1970-2018 with keywords baclofen, spinal cord injury, and efficacy.

      Study Selection

      The database search yielded 588 sources and 10 additional relevant publications. After removal of duplicates, 398 publications were screened.

      Data Extraction

      Data were extracted using the following population, intervention, comparator, outcomes, and study designs criteria: studies including adult patients with SCI with spasticity; the intervention could be oral or intrathecal administration of baclofen; selection was inclusive for control groups, surgical management, rehabilitation, and alternative pharmaceutical agents; outcomes were efficacy, dosing, and adverse events. Randomized controlled trials, observational studies, and case reports were included. Meta-analyses and systematic reviews were excluded.

      Data Synthesis

      A total of 98 studies were included with 1943 patients. Only 4 randomized, double-blinded, and placebo-controlled trials were reported. Thirty-nine studies examined changes in the Modified Ashworth Scale (MAS; 34 studies) and Penn Spasm scores (Penn Spasm Frequency; 19 studies), with average reductions of 1.7±1.3 and 1.6±1.4 in individuals with SCI, respectively. Of these data, a total of 6 of the 34 studies (MAS) and 2 of the 19 studies (Penn Spasm Frequency) analyzed oral baclofen. Forty-three studies addressed adverse events with muscle weakness and fatigue frequently reported.

      Conclusions

      Baclofen is the most commonly-prescribed antispasmodic after SCI. Surprisingly, there remains a significant lack of large, placebo-controlled, double-blinded clinical trials, with most efficacy data arising from small studies examining treatment across different etiologies. In the studies reviewed, baclofen effectively improved spasticity outcome measures, with increased efficacy through intrathecal administration. Few studies assessed how reduced neural excitability affected residual motor function and activities of daily living. A host of adverse events were reported that may negatively affect quality of life. Comparative randomized controlled trials of baclofen and alternative treatments are warranted because these have demonstrated promise in relieving spasticity with reduced adverse events and without negatively affecting residual motor function.

      Keywords

      List of abbreviations:

      ADL (activities of daily living), AIS (American Spinal Injury Association Impairment Scale), GABA (gamma-aminobutyric acid), MAS (Modified Ashworth Scale), mMRC (modified Medical Research Council), SCI (spinal cord injury)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Archives of Physical Medicine and Rehabilitation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sekhon LH
        • Fehlings MG
        Epidemiology, demographics, and pathophysiology of acute spinal cord injury.
        Spine (Phila Pa 1976). 2001; 26: S2-12
        • Singh A
        • Tetreault L
        • Kalsi-Ryan S
        • Nouri A
        • Fehlings MG
        Global prevalence and incidence of traumatic spinal cord injury.
        Clin Epidemiol. 2014; 6: 309-331
        • Biering-Sorensen F
        • Nielsen JB
        • Klinge K
        Spasticity-assessment: a review.
        Spinal Cord. 2006; 44: 708-722
        • Pandyan AD
        • Gregoric M
        • Barnes MP
        • et al.
        Spasticity: clinical perceptions, neurological realities and meaningful measurement.
        Disabil Rehabil. 2005; 27: 2-6
        • Maynard FM
        • Karunas RS
        • Waring 3rd, WP
        Epidemiology of spasticity following traumatic spinal cord injury.
        Arch Phys Med Rehabil. 1990; 71: 566-569
        • Sherrington CS
        Decerebrate rigidity, and reflex coordination of movements.
        J Physiol. 1898; 22: 319-332
        • Skold C
        • Levi R
        • Seiger A
        Spasticity after traumatic spinal cord injury: nature, severity, and location.
        Arch Phys Med Rehabil. 1999; 80: 1548-1557
        • Dietz V
        Spastic movement disorder.
        Spinal Cord. 2000; 38: 389-393
        • McKay WB
        • Sweatman WM
        • Field-Fote EC
        The experience of spasticity after spinal cord injury: perceived characteristics and impact on daily life.
        Spinal Cord. 2018; 56: 478-486
        • Levi R
        • Hultling C
        • Seiger A
        The Stockholm Spinal Cord Injury Study. 3. Health-related issues of the Swedish Annual Level-of-Living Survey in SCI subjects and controls.
        Paraplegia. 1995; 33: 726-730
        • Andresen SR
        • Biering-Sorensen F
        • Hagen EM
        • Nielsen JF
        • Bach FW
        • Finnerup NB
        Pain, spasticity and quality of life in individuals with traumatic spinal cord injury in Denmark.
        Spinal Cord. 2016; 54: 973-979
        • Little JW
        • Micklesen P
        • Umlauf R
        • Britell C
        Lower extremity manifestations of spasticity in chronic spinal cord injury.
        Am J Phys Med Rehabil. 1989; 68: 32-36
        • Tibbett J
        • Widerstrom-Noga EG
        • Thomas CK
        • Field-Fote EC
        Impact of spasticity on transfers and activities of daily living in individuals with spinal cord injury.
        J Spinal Cord Med. 2019; 42: 318-327
        • Mailis A
        • Ashby P
        Alterations in group Ia projections to motoneurons following spinal lesions in humans.
        J Neurophysiol. 1990; 64: 637-647
        • Faist M
        • Mazevet D
        • Dietz V
        • Pierrot-Deseilligny E
        A quantitative assessment of presynaptic inhibition of Ia afferents in spastics. Differences in hemiplegics and paraplegics.
        Brain. 1994; 117: 1449-1455
        • Aymard C
        • Katz R
        • Lafitte C
        • et al.
        Presynaptic inhibition and homosynaptic depression: a comparison between lower and upper limbs in normal human subjects and patients with hemiplegia.
        Brain. 2000; 123: 1688-1702
        • Crone C
        • Nielsen J
        • Petersen N
        • Ballegaard M
        • Hultborn H
        Disynaptic reciprocal inhibition of ankle extensors in spastic patients.
        Brain. 1994; 117: 1161-1168
        • Crone C
        • Nielsen J
        Central control of disynaptic reciprocal inhibition in humans.
        Acta Physiol Scand. 1994; 152: 351-363
        • Crone C
        • Petersen NT
        • Nielsen JE
        • Hansen NL
        • Nielsen JB
        Reciprocal inhibition and corticospinal transmission in the arm and leg in patients with autosomal dominant pure spastic paraparesis (ADPSP).
        Brain. 2004; 127: 2693-2702
        • Calancie B
        • Broton JG
        • Klose KJ
        • Traad M
        • Difini J
        • Ayyar DR.
        Evidence that alterations in presynaptic inhibition contribute to segmental hypo- and hyperexcitability after spinal cord injury in man.
        Electroencephalogr Clin Neurophysiol. 1993; 89: 177-186
        • Schindler-Ivens S
        • Shields RK.
        Low frequency depression of H-reflexes in humans with acute and chronic spinal-cord injury.
        Exp Brain Res. 2000; 133: 233-241
        • Roby-Brami A
        • Bussel B.
        Long-latency spinal reflex in man after flexor reflex afferent stimulation.
        Brain. 1987; 110: 707-725
        • D'Amico JM
        • Condliffe EG
        • Martins KJ
        • Bennett DJ
        • Gorassini MA.
        Recovery of neuronal and network excitability after spinal cord injury and implications for spasticity.
        Front Integr Neurosci. 2014; 8: 36
        • Sinkjaer T
        • Toft E
        • Larsen K
        • Andreassen S
        • Hansen HJ.
        Non-reflex and reflex mediated ankle joint stiffness in multiple sclerosis patients with spasticity.
        Muscle Nerve. 1993; 16: 69-76
        • Schindler-Ivens SM
        • Shields RK.
        Comparison of linear regression and probit analysis for detecting H-reflex threshold in individuals with and without spinal cord injury.
        Electromyogr Clin Neurophysiol. 2004; 44: 153-159
        • Mutlu A
        • Livanelioglu A
        • Gunel MK.
        Reliability of Ashworth and Modified Ashworth Scales in children with spastic cerebral palsy.
        BMC Musculoskelet Disord. 2008; 9: 44
        • Bohannon RW
        • Smith MB.
        Interrater reliability of a Modified Ashworth Scale of muscle spasticity.
        Phys Ther. 1987; 67: 206-207
        • Fleuren JF
        • Voerman GE
        • Erren-Wolters CV
        • et al.
        Stop using the Ashworth Scale for the assessment of spasticity.
        J Neurol Neurosurg Psychiatry. 2010; 81: 46-52
        • Ashworth B
        Preliminary trial of carisoprodol in multiple sclerosis.
        Practitioner. 1964; 192: 540-542
        • Penn RD
        • Savoy SM
        • Corcos D
        • et al.
        Intrathecal baclofen for severe spinal spasticity.
        N Engl J Med. 1989; 320: 1517-1521
        • Baunsgaard CB
        • Nissen UV
        • Christensen KB
        Biering-Sorensen F. Modified Ashworth Scale and spasm frequency score in spinal cord injury: reliability and correlation.
        Spinal Cord. 2016; 54: 702-708
        • Haugh AB
        • Pandyan AD
        • Johnson GR.
        A systematic review of the Tardieu Scale for the measurement of spasticity.
        Disabil Rehabil. 2006; 28: 899-907
        • Akpinar P
        • Atici A
        • Ozkan FU
        • et al.
        Reliability of the Modified Ashworth Scale and Modified Tardieu Scale in patients with spinal cord injuries.
        Spinal Cord. 2017; 55: 944-949
        • Sammaraiee Y
        • Yardley M
        • Keenan L
        • Buchanan K
        • Stevenson V
        • Farrell R
        Intrathecal baclofen for multiple sclerosis related spasticity: a twenty year experience.
        Mult Scler Relat Disord. 2018; 27: 95-100
        • Penn RD.
        Intrathecal baclofen for spasticity of spinal origin: seven years of experience.
        J Neurosurg. 1992; 77: 236-240
        • Curtis DR
        • Gynther BD
        • Lacey G
        • Beattie DT.
        Baclofen: reduction of presynaptic calcium influx in the cat spinal cord in vivo.
        Exp Brain Res. 1997; 113: 520-533
        • Shimizu T
        • Hino T
        • Komori T
        • Hirai S.
        Loss of the muscle silent period evoked by transcranial magnetic stimulation of the motor cortex in patients with cervical cord lesions.
        Neurosci Lett. 2000; 286: 199-202
        • Kumru H
        • Kofler M.
        Effect of spinal cord injury and of intrathecal baclofen on brainstem reflexes.
        Clin Neurophysiol. 2012; 123: 45-53
        • Ochs G
        • Struppler A
        • Meyerson BA
        • et al.
        Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.
        J Neurol Neurosurg Psychiatry. 1989; 52: 933-939
        • Balsara K
        • Jea A
        • Raskin JS.
        Neurosurgical management of spastic conditions of the upper extremity.
        Hand Clin. 2018; 34: 547-554
        • Ertzgaard P
        • Campo C
        • Calabrese A.
        Efficacy and safety of oral baclofen in the management of spasticity: a rationale for intrathecal baclofen.
        J Rehabil Med. 2017; 49: 193-203
        • Coffey JR
        • Cahill D
        • Steers W
        • et al.
        Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study.
        J Neurosurg. 1993; 78: 226-232
        • Wainberg M
        • Barbeau H
        • Gauthier S.
        Quantitative assessment of the effect of cyproheptadine on spastic paretic gait: a preliminary study.
        J Neurol. 1986; 233: 311-314
        • Angeli C
        • Ochsner J
        • Harkema S.
        Effects of chronic baclofen use on active movement in an individual with a spinal cord injury.
        Spinal Cord. 2012; 50: 925-927
        • Barbeau H
        • Norman KE.
        The effect of noradrenergic drugs on the recovery of walking after spinal cord injury.
        Spinal Cord. 2003; 41: 137-143
        • Norman KE
        • Pepin A
        • Barbeau H.
        Effects of drugs on walking after spinal cord injury.
        Spinal Cord. 1998; 36: 699-715
        • Hobart JC
        • Thompson AJ.
        The five item Barthel Index.
        J Neurol Neurosurg Psychiatry. 2001; 71: 225-230
        • Sinoff G
        • Ore L.
        The Barthel Activities of Daily Living Index: self-reporting versus actual performance in the old-old (>or = 75 years).
        J Am Geriatr Soc. 1997; 45: 832-836
        • Moher D
        • Liberati A
        • Tetzlaff J
        • Altman DG
        • PRISMA Group
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        J Clin Epidemiol. 2009; 62: 1006-1012
        • Yan X
        • Lan J
        • Liu Y
        • Miao J.
        Efficacy and safety of botulinum toxin type A in spasticity caused by spinal cord injury: a randomized, controlled trial.
        Med Sci Monit. 2018; 24: 8160-8171
        • Kumru H
        • Benito-Penalva J
        • Kofler M
        • Vidal J.
        Analgesic effect of intrathecal baclofen bolus on neuropathic pain in spinal cord injury patients.
        Brain Res Bull. 2018; 140: 205-211
        • Luo D
        • Wu G
        • Ji Y
        • et al.
        The comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury.
        Saudi Pharm J. 2017; 25: 655-659
        • Nance PW
        • Huff FJ
        • Martinez-Arizala A
        • et al.
        Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury.
        Spinal Cord. 2011; 49: 974-980
        • Bravo-Esteban E
        • Taylor J
        • Abian-Vicen J
        • et al.
        Impact of specific symptoms of spasticity on voluntary lower limb muscle function, gait and daily activities during subacute and chronic spinal cord injury.
        NeuroRehabilitation. 2013; 33: 531-543
        • Kitade I
        • Arishima H
        • Kikuta KI.
        Effect of the intrathecal baclofen screening test on the spatiotemporal gait motion parameters of patients with cervical spinal cord injuries who exhibited diffuse spasticity: a report of three cases.
        NMC Case Rep J. 2014; 1: 20-23
        • Clearfield JS
        • Nelson ME
        • McGuire J
        • Rein LE
        • Tarima S.
        Intrathecal baclofen dosing regimens: a retrospective chart review.
        Neuromodulation. 2016; 19: 642-649
        • Azouvi P
        • Mane M
        • Thiebaut JB
        • Denys P
        • Remy-Neris O
        • Bussel B.
        Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up.
        Arch Phys Med Rehabil. 1996; 77: 35-39
        • Chumney D
        • Nollinger K
        • Shesko K
        • Skop K
        • Spencer M
        • Newton RA.
        Ability of Functional Independence Measure to accurately predict functional outcome of stroke-specific population: systematic review.
        J Rehabil Res Dev. 2010; 47: 17-29
        • Becker WJ
        • Harris CJ
        • Long ML
        • Ablett DP
        • Klein GM
        • DeForge DA.
        Long-term intrathecal baclofen therapy in patients with intractable spasticity.
        Can J Neurol Sci. 1995; 22: 208-217
        • Coffey RJ
        • Edgar TS
        • Francisco GE
        • et al.
        Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome.
        Arch Phys Med Rehabil. 2002; 83: 735-741
        • Wu X
        • Liu J
        • Tanadini LG
        • et al.
        Challenges for defining minimal clinically important difference (MCID) after spinal cord injury.
        Spinal Cord. 2015; 53: 84-91
        • Musselman KE
        • Yang JF.
        Walking tasks encountered by urban-dwelling adults and persons with incomplete spinal cord injuries.
        J Rehabil Med. 2007; 39: 567-574
        • Lam T
        • Noonan VK
        • Eng JJ
        • Team SR.
        A systematic review of functional ambulation outcome measures in spinal cord injury.
        Spinal Cord. 2008; 46: 246-254
        • Alibiglou L
        • Rymer WZ
        • Harvey RL
        • Mirbagheri MM.
        The relation between Ashworth scores and neuromechanical measurements of spasticity following stroke.
        J Neuroeng Rehabil. 2008; 5: 18
        • Kawano O
        • Masuda M
        • Takao T
        • et al.
        The dosage and administration of long-term intrathecal baclofen therapy for severe spasticity of spinal origin.
        Spinal Cord. 2018; 56: 996-999
      1. Rehab measure: Ashworth Scale/Modified Ashworth Scale. Available at: https://www.sralab.org/rehabilitation-measures/ashworth-scale-modified-ashworth-scale. Accessed August 2021.

        • Chang E
        • Ghosh N
        • Yanni D
        • Lee S
        • Alexandru D
        • Mozaffar T.
        A review of spasticity treatments: pharmacological and interventional approaches.
        Crit Rev Phys Rehabil Med. 2013; 25: 11-22
        • Theriault ER
        • Huang V
        • Whiteneck G
        • Dijkers MP
        • Harel NY.
        Antispasmodic medications may be associated with reduced recovery during inpatient rehabilitation after traumatic spinal cord injury.
        J Spinal Cord Med. 2018; 41: 63-71
        • Nance PW.
        A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients.
        J Am Paraplegia Soc. 1994; 17: 150-156
        • Wainberg M
        • Barbeau H
        • Gauthier S.
        The effects of cyproheptadine on locomotion and on spasticity in patients with spinal cord injuries.
        J Neurol Neurosurg Psychiatry. 1990; 53: 754-763
        • Nance PW
        • Bugaresti J
        • Shellenberger K
        • Sheremata W
        • Martinez-Arizala A.
        Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
        Neurology. 1994; 44 ([discussion: S51-2]): S44-S51
        • Newman PM
        • Nogues M
        • Newman PK
        • Weightman D
        • Hudgson P.
        Tizanidine in the treatment of spasticity.
        Eur J Clin Pharmacol. 1982; 23: 31-35
        • Kaddar N
        • Vigneault P
        • Pilote S
        • Patoine D
        • Simard C
        • Drolet B.
        Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr.
        J Cardiovasc Pharmacol Ther. 2012; 17: 102-109
        • Polc P
        • Mohler H
        • Haefely W.
        The effect of diazepam on spinal cord activities: possible sites and mechanisms of action.
        Naunyn Schmiedebergs Arch Pharmacol. 1974; 284: 319-337
        • Sieghart W.
        Pharmacology of benzodiazepine receptors: an update.
        J Psychiatry Neurosci. 1994; 19: 24-29
        • Taylor CP.
        Emerging perspectives on the mechanism of action of gabapentin.
        Neurology. 1994; 44 (-6 [discussion: S31-2]): S10
        • Sills GJ.
        The mechanisms of action of gabapentin and pregabalin.
        Curr Opin Pharmacol. 2006; 6: 108-113
        • Das TK
        • Park DM.
        Botulinum toxin in treating spasticity.
        Br J Clin Pract. 1989; 43: 401-403
        • Das TK
        • Park DM.
        Effect of treatment with botulinum toxin on spasticity.
        Postgrad Med J. 1989; 65: 208-210
        • Simpson LL.
        Identification of the major steps in botulinum toxin action.
        Annu Rev Pharmacol Toxicol. 2004; 44: 167-193
        • Fortuna R
        • Horisberger M
        • Vaz MA
        • Herzog W.
        Do skeletal muscle properties recover following repeat onabotulinum toxin A injections?.
        J Biomech. 2013; 46: 2426-2433
        • Bovend'Eerdt TJ
        • Newman M
        • Barker K
        • Dawes H
        • Minelli C
        • Wade DT.
        The effects of stretching in spasticity: a systematic review.
        Arch Phys Med Rehabil. 2008; 89: 1395-1406
        • Harvey LA
        • Herbert RD
        • Glinsky J
        • Moseley AM
        • Bowden J.
        Effects of 6 months of regular passive movements on ankle joint mobility in people with spinal cord injury: a randomized controlled trial.
        Spinal Cord. 2009; 47: 62-66
        • Odeen I
        • Knutsson E.
        Evaluation of the effects of muscle stretch and weight load in patients with spastic paraplegia.
        Scand J Rehabil Med. 1981; 13: 117-121
        • Rayegani SM
        • Shojaee H
        • Sedighipour L
        • Soroush MR
        • Baghbani M
        • Amirani OB.
        The effect of electrical passive cycling on spasticity in war veterans with spinal cord injury.
        Front Neurol. 2011; 2: 39
        • Gorassini MA
        • Norton JA
        • Nevett-Duchcherer J
        • Roy FD
        • Yang JF.
        Changes in locomotor muscle activity after treadmill training in subjects with incomplete spinal cord injury.
        J Neurophysiol. 2009; 101: 969-979
        • Adams MM
        • Hicks AL.
        Comparison of the effects of body-weight-supported treadmill training and tilt-table standing on spasticity in individuals with chronic spinal cord injury.
        J Spinal Cord Med. 2011; 34: 488-494
        • Manella KJ
        • Field-Fote EC.
        Modulatory effects of locomotor training on extensor spasticity in individuals with motor-incomplete spinal cord injury.
        Restor Neurol Neurosci. 2013; 31: 633-646
        • Jayaraman A
        • Thompson CK
        • Rymer WZ
        • Hornby TG.
        Short-term maximal-intensity resistance training increases volitional function and strength in chronic incomplete spinal cord injury: a pilot study.
        J Neurol Phys Ther. 2013; 37: 112-117
      2. Hsieh JTC, Wolfe DL, McIntyre A, et al. Spasticity following spinal cord injury. 2012. Available at: https://scireproject.com/wp-content/uploads/2022/04/spasticity_V7.pdf. Accessed August 25, 2022.

        • Marsolais EB
        • Kobetic R.
        Development of a practical electrical stimulation system for restoring gait in the paralyzed patient.
        Clin Orthop Relat Res. 1988; : 64-74
        • van der Salm A
        • Veltink PH
        • Ijzerman MJ
        • Groothuis-Oudshoorn KC
        • Nene AV
        • Hermens HJ.
        Comparison of electric stimulation methods for reduction of triceps surae spasticity in spinal cord injury.
        Arch Phys Med Rehabil. 2006; 87: 222-228
        • Carty A
        • McCormack K
        • Coughlan GF
        • Crowe L
        • Caulfield B.
        Alterations in body composition and spasticity following subtetanic neuromuscular electrical stimulation training in spinal cord injury.
        J Rehabil Res Dev. 2013; 50: 193-202
        • Aydin G
        • Tomruk S
        • Keles I
        • Demir SO
        • Orkun S.
        Transcutaneous electrical nerve stimulation versus baclofen in spasticity: clinical and electrophysiologic comparison.
        Am J Phys Med Rehabil. 2005; 84: 584-592
        • Kumru H
        • Murillo N
        • Samso JV
        • et al.
        Reduction of spasticity with repetitive transcranial magnetic stimulation in patients with spinal cord injury.
        Neurorehabil Neural Repair. 2010; 24: 435-441
        • Nardone R
        • De Blasi P
        • Holler Y
        • et al.
        Repetitive transcranial magnetic stimulation transiently reduces punding in Parkinson's disease: a preliminary study.
        J Neural Transm (Vienna). 2014; 121: 267-274
        • Nardone R
        • Brigo F
        • Versace V
        • et al.
        Cortical afferent inhibition abnormalities reveal cholinergic dysfunction in Parkinson's disease: a reappraisal.
        J Neural Transm (Vienna). 2017; 124: 1417-1429
        • Nagel SJ
        • Wilson S
        • Johnson MD
        • et al.
        Spinal cord stimulation for spasticity: historical approaches, current status, and future directions.
        Neuromodulation. 2017; 20: 307-321
        • Mesbah S
        • Ball T
        • Angeli C
        • et al.
        Predictors of volitional motor recovery with epidural stimulation in individuals with chronic spinal cord injury.
        Brain. 2021; 144: 420-433
        • Pinter MM
        • Gerstenbrand F
        • Dimitrijevic MR.
        Epidural electrical stimulation of posterior structures of the human lumbosacral cord: 3. Control of spasticity.
        Spinal Cord. 2000; 38: 524-531
        • Hofstoetter US
        • Freundl B
        • Danner SM
        • et al.
        Transcutaneous spinal cord stimulation induces temporary attenuation of spasticity in individuals with spinal cord injury.
        J Neurotrauma. 2020; 37: 481-493
        • Hofstoetter US
        • McKay WB
        • Tansey KE
        • Mayr W
        • Kern H
        • Minassian K.
        Modification of spasticity by transcutaneous spinal cord stimulation in individuals with incomplete spinal cord injury.
        J Spinal Cord Med. 2014; 37: 202-211